Cost of Illness Analysis of Self-Injection of Biologics in Patients With Rheumatoid Arthritis in Japan
Author(s)
Kazuhiko Takahata, MSc1, Eiichi Tanaka, MD, PhD2, RYOKO SAKAI, PhD, MPH1, Manabu Akazawa, PhD, MPH1.
1Meiji Pharmaceutical University, Kiyose-shi, Japan, 2Tokyo Women’s Medical University School of Medicine, Shinjuku, Japan.
1Meiji Pharmaceutical University, Kiyose-shi, Japan, 2Tokyo Women’s Medical University School of Medicine, Shinjuku, Japan.
OBJECTIVES: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective treatments for rheumatoid arthritis (RA), however, their high cost is a significant concern. Self-injection (SI) of bDMARDs may reduce the frequency of hospital visits and associated costs, but its overall economic impact remains unclear. This study evaluated the effect of SI on healthcare costs from a societal perspective.
METHODS: A cost of illness model was developed using real-world data from a Japanese claims database (DeSC Healthcare), patient survey data (Medilead Inc.), and publicly available government sources. Patients with RA using SI (SI group) were compared with those not using SI (non-SI group). Direct healthcare costs (e.g., drug costs, consultation fees), direct non-healthcare costs (e.g., travel costs), and indirect costs (e.g., productivity loss) were estimated. Annual costs were calculated for both groups, and sensitivity analyses were conducted based on travel costs and hourly wage assumptions.
RESULTS: Annual total healthcare costs were higher in the SI group (10,065 USD) than in the non-SI group (7,963 USD), using an exchange rate of 150 yen per USD. This difference was mainly due to higher bDMARD costs in the SI group, where patients received an average of 3 prescriptions (726 USD/month) compared to 2 prescriptions (501 USD/month) in the non-SI group. Although the SI group had fewer hospital visits (9.5 vs. 25 per year), total healthcare costs per visit were higher. Other cost categories (e.g., other disease-modifying antirheumatic drugs, examination and rehabilitation) were similar between the groups. Sensitivity analyses indicated that SI could become cost-saving if travel costs per visit exceeded 139 USD or hourly wages exceeded 80 USD.
CONCLUSIONS: Although SI of bDMARD may involve higher direct medical costs, it has the potential to be advantageous in terms of overall societal costs by reducing work-related and caregiving burdens.
METHODS: A cost of illness model was developed using real-world data from a Japanese claims database (DeSC Healthcare), patient survey data (Medilead Inc.), and publicly available government sources. Patients with RA using SI (SI group) were compared with those not using SI (non-SI group). Direct healthcare costs (e.g., drug costs, consultation fees), direct non-healthcare costs (e.g., travel costs), and indirect costs (e.g., productivity loss) were estimated. Annual costs were calculated for both groups, and sensitivity analyses were conducted based on travel costs and hourly wage assumptions.
RESULTS: Annual total healthcare costs were higher in the SI group (10,065 USD) than in the non-SI group (7,963 USD), using an exchange rate of 150 yen per USD. This difference was mainly due to higher bDMARD costs in the SI group, where patients received an average of 3 prescriptions (726 USD/month) compared to 2 prescriptions (501 USD/month) in the non-SI group. Although the SI group had fewer hospital visits (9.5 vs. 25 per year), total healthcare costs per visit were higher. Other cost categories (e.g., other disease-modifying antirheumatic drugs, examination and rehabilitation) were similar between the groups. Sensitivity analyses indicated that SI could become cost-saving if travel costs per visit exceeded 139 USD or hourly wages exceeded 80 USD.
CONCLUSIONS: Although SI of bDMARD may involve higher direct medical costs, it has the potential to be advantageous in terms of overall societal costs by reducing work-related and caregiving burdens.
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD95
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)